News The latest developments in autism research.
Profiles Portraits of scientists who are making a mark on autism research.
Toolbox Emerging tools and techniques that may advance autism research.
Spotted A roundup of autism papers and media mentions you may have missed.
Opinion Conversations on the science of autism research.
Viewpoint Expert opinions on trends and controversies in autism research.
Columnists Dispatches from experts on various facets of autism.
Crosstalk Debates and conversations about timely topics in autism.
Reviews Exploring the intersection of autism and the arts.
Q&A Conversations with experts about noteworthy topics in autism.
Deep Dive In-depth analysis of important topics in autism.
Special Reports Curated collections of articles on special topics in autism.
Webinars Presentations by leading experts on their latest research.
Features / Webinars

Jeremy Veenstra-VanderWeele talks routes to treatment

25 June 2014
The Presenter

Jeremy Veenstra-VanderWeele

Associate Professor of Psychiatry, Pediatrics, and Pharmacology, Vanderbilt University School of Medicine

Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.

On 25 June, Jeremy Veenstra-VanderWeele laid out two conceptual paths forward for developing effective autism drugs — one that focuses on the total group of people affected by autism but that might only provide modest relief, and another that could be transformative but focuses on a subset of individuals with the disorder.

Veenstra-VanderWeele is medical director of the Treatment and Research Institute for Autism Spectrum Disorders at Vanderbilt University in Nashville, Tennessee.

You can watch a complete replay of the webinar above.

Use the comments section below to submit questions we didn’t have time to discuss during the Q&A session or to pose follow-up questions for Veenstra-VanderWeele.

Press Policy
The Spectrum Webinar Series aims to facilitate the free exchange of ideas among autism researchers, including discussion of published and unpublished research, hypotheses and results. Members of the press may report information presented during a Spectrum webinar only if that material has already been published elsewhere or they have first obtained express written consent from the presenter.

About Webinars
Presentations by leading experts that showcase new findings, useful techniques and emerging topics in autism research. We invite questions before and during the presentations in the Comments section.
  • doris

    the use of probiotics would be helpful. my son has benefited from them in calming irritable bowel syndrome . showing improved functioning. he is 62 years old.

  • Judith Miles, MD, PhD

    Will you discuss genetic testing of individual patient’s response to specific drugs to make informed medication decisions by determining metabolism rates?

    • Jeremy Veenstra-VanderWeele, MD

      Hi Dr. Miles,

      I was not planning to discuss CYP genotyping in this talk. We could certainly discuss it in the question-answer period.

      Best regards,


  • edward Quadros

    The presenter did not touch upon the recent observation of folate receptor autoimmune disorder with a biomarker in the form of serum autoantibodies against the folate receptor alpha. These children respond very well to high dose folinic acid. Folate is involved in some very basic metabolic processes including epigenetic regulation of gene expression. It exerts its effects on brain development during fetal life as well as early infancy. High dose folinic acid intervention during pregnancy and early infancy could potentially benefit those those at risk


Log in to your Spectrum Wiki account

Email Address:



Request your Spectrum Wiki account

Spectrum Wiki is a community of researchers affiliated with an academic or research institutions. To be considered for participation, please fill out this form and a member of our team will respond to your request.


Email Address:

Title and Lab:

Area of Expertise: